Recent clinical studies have shown the efficacy of venetoclax (an inhibitor of the anti-apoptotic Bcl-2 protein) in the treatment of older NPM1-mut AML patients when administered together with hypomethylating agents [94,95] or low-dose AraC [96,97] or intensive chemotherapy [98,99]. Here, NPM1 is linked to acute myeloid leukemia.